Abstract
Introduction: The AMAROS and Z011 trials showed non-inferiority of axillary radiotherapy to standard axillary clearance (ANC) in patients with N1 disease with significant reduced morbidity. Targeted axillary dissection (TAD) to stage N1 axilla in selected cases can help guide axillary de-escalation. This prospective tertiary centre study aimed to assess the feasibility of utilising TAD in selected patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
